Dianthus Therapeutics, Inc.
DNTH
Rang in Aktien
#3773
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Aktienkurs
$79.23
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$4.43B
Veränderung (1 Tag)
6.29%
Veränderung (1 Jahr)
126.18%
Land
US
Handel Dianthus Therapeutics, Inc. (DNTH)
Kategorie
Healthcare
Kursverlauf für Dianthus Therapeutics, Inc. (DNTH)
Höchster Schlusskurs: $80.96 am 2026-10-01
Niedrigster Schlusskurs: $225.69 am 2018-06-01
Niedrigster Schlusskurs: $225.69 am 2018-06-01
Kursverlauf der Aktie von Dianthus Therapeutics, Inc. von 2018 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 74.00% |
| 2025 | 79.27% |
| 2024 | 158.65% |
| 2023 | -30.65% |
| 2022 | -83.63% |
| 2021 | -32.46% |
| 2020 | -46.40% |
| 2019 | 100.40% |
| 2018 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $514.65 | 20.73% |
US
|
|
| $242.08 | 780.61% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $869.72 | 4.19% |
NL
|
|
| $750.93 | 7.12% |
CH
|
